Journal for ImmunoTherapy of Cancer
ISSN: 2051-1426
Publisher: BioMed Central
Publications (51)
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? (2020)
Constantinescu C, Pasca S, Tat T, Teodorescu P, Vlad C, Iluta S, Dima D, et al.
Journal article, Review article
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG (2020)
Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, et al.
Journal article
Inhibition of TGF- β- Receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer (2020)
Stuber T, Monjezi R, Wallstabe L, Kuehnemundt J, Nietzer SL, Dandekar G, Woeckel A, et al.
Journal article
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020)
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, et al.
Journal article, Review article
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (2020)
Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, et al.
Journal article
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study (2019)
Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, et al.
Journal article
A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019)
Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors (2019)
Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, et al.
Journal article
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells (2018)
Jitschin R, Saul D, Braun M, Tohumeken S, Kischel R, Lutteropp M, Dos Santos C, et al.
Journal article
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports (2018)
Schliep S, Agaimy A, Kiesewetter F, Schuler G, Heinzerling L, Cavallaro AJ
Journal article